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Tuberculin skin testing underestimates a high prevalence of la-
tent tuberculosis infection in hemodialysis patients.
Background. Identification of latent Mycobacterium tuber-
culosis infection in hemodialysis patients is hampered by re-
duced sensitivity of the established tuberculin skin test. We
investigated whether in vitro quantitation of purified protein
derivative (PPD)–specific T cells using a rapid 6-hour assay may
represent an alternative approach for detecting latent infection.
Methods. One hundred and twenty-seven hemodialysis pa-
tients and 218 control patients (blood donors, health care work-
ers, and control patients) were analyzed. Specific T cells toward
PPD and early secretory antigenic target-6 (ESAT-6), a pro-
tein expressed in Mycobacterium tuberculosis but absent from
M. bovis bacillus Calmette-Guerin (BCG) vaccine strains, were
flow cytometrically quantified from whole blood, and results
were compared with skin testing.
Results. Compared to blood donors, a high proportion of
both health care workers (48.6%) and hemodialysis patients
(53.5%) had PPD-specific Th1-type CD4 T-cell reactivity with
similar median frequencies of PPD-specific T cells (0.17%; 0.06–
3.75% vs. 0.26%; 0.06–4.12%, respectively). In contrast, skin
test reactivity was significantly reduced in hemodialysis pa-
tients. Whereas 85.7% of control patients with PPD reactivity in
vitro were skin test–positive, the respective percentage among
hemodialysis patients was 51.4% (P = 0.007). Among individ-
uals with PPD reactivity in vitro, ∼50% had T cells specific for
ESAT-6.
Conclusion. Unlike the skin test, measurement of PPD
reactivity by in vitro quantitation of PPD-specific T cells
was unaffected by uremia-associated immunosuppression. This
whole-blood assay may thus be a valuable alternative to skin
testing, and detection of ESAT-6–specific T cells could more-
over allow distinction of latent M. tuberculosis infection from
BCG-induced reactivity to PPD. The assay is well suited for
clinical use and may facilitate targeting of preventative therapy
in high-risk individuals.
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Tuberculosis is one of the leading infectious diseases
in man that accounts for around eight million cases and
nearly three million deaths annually. The disease is caused
by infection with Mycobacterium tuberculosis and rep-
resents an important cause of morbidity and mortality,
especially among immunocompromised individuals [1].
Because of systemic immunosuppression, individuals
such as human immunodeficiency virus (HIV)-infected
patients, transplant recipients, and hemodialysis patients
with M. tuberculosis infection are at increased risk of pro-
gression to active disease. Chronic renal failure is asso-
ciated with a state of uremic immunodeficiency that is
clinically characterized by a high incidence of infectious
complications and attendant mortality [2], by an impaired
response to vaccinations, and by reduced delayed-type
hypersensitivity reactions [3–6]. The molecular basis for
the altered in vivo immune response is associated with im-
paired activation of T cells [7, 8]. The defect itself resides
in antigen-presenting cells [9], as it may be compensated
in vitro by the application of costimulatory signals of the
B7/CD28-pathway [10, 11]. Apart from an altered costim-
ulatory capacity, we and others found a bias of T-helper
cell responses (Th) toward Th1 [12], and an increased pro-
duction of proinflammatory cytokines in monocytes from
patients undergoing chronic intermittent hemodialysis
[13–15]. Interestingly, as with decreased costimulatory
capacity, the extent of expression of proinflammatory
cytokines also correlates with the severity of clinical
immunodeficiency [14].
Prevention of the development of active tuberculosis
critically depends on sensitive diagnostic tests to iden-
tify latently infected individuals. A latent infection is typ-
ically characterized by a relatively strong PPD-specific
immune response in the absence of detectable bacterial
load. The tuberculin skin test is currently the only widely
used diagnostic method for the identification of an M. tu-
berculosis infection in individuals without disease [16]. A
major disadvantage of the tuberculin skin test is the im-
paired sensitivity in high-risk groups of immunocompro-
mised patients. Based on sensitivity, specificity, and on the
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prevalence of tuberculosis, different cutpoints have been
suggested for defining a positive skin-test reaction, and
for recommendations for prophylaxis [17, 18]. A cutpoint
of ≥15 mm applies to immunocompetent individuals.
In contrast, for individuals with mildly impaired im-
munity such as hemodialysis patients, a lower thresh-
old of ≥10 mm is suggested. Nevertheless, depending
on the extent of immunosuppression, the actual num-
ber of latently infected individuals may be considerably
underestimated [5, 6].
At present, there is no standard diagnostic test to di-
agnose latent tuberculosis infections in anergic patients.
This would be of considerable clinical importance, as
this could aid in identifying latently infected patients,
and in targeting appropriate preventative therapy be-
fore transplantation. Recently, a number of assays sys-
tems have been described that allow the rapid analysis of
pathogen-specific T-cell immunity in vitro [19–21]. This
study was performed to characterize the T-cell response
toward purified protein derivative (PPD) from M. tuber-
culosis and to analyze whether its direct quantitation from
whole blood could represent an alternative approach to
the skin test in anergic and/or immunocompromised pa-
tients. Moreover, reactivity toward the recombinant early
secretory antigenic target 6 (ESAT-6) protein, which is
absent from all strains of the M. bovis bacillus Calmette-
Guerin (BCG) vaccine, was analyzed to distinguish
true M. tuberculosis-specific immune responses from
vaccination-induced responses. Hemodialysis patients
with uremia-associated immunodeficiency were chosen
as a group of individuals with increased risk for progres-
sion to active disease. Immunocompetent medical staff
as well as healthy blood donors were studied as con-
trols for individuals with similar or low risk of exposure,
respectively.
METHODS
Subjects
The study was conducted among 127 hemodialysis pa-
tients (61.2 ± 15.2 years) and 218 immunocompetent
control individuals (44.0 ± 14.8 years) of Caucasian ori-
gin. Control individuals consisted of health care workers
(N = 107), immunocompetent patients (N = 59) who
were admitted to the Medical Departments IV and V
(University of the Saarland, Germany), and who under-
went a routine screening for PPD-specific T-cell reactiv-
ity between December 2001 and December 2002, and
healthy blood donors (N = 52). Study participants had
no signs or symptoms of active tuberculosis. Subclinical
infections were also unlikely because patients were seen
regularly, and none of the individuals have presented with
active disease during the 8-month period since the end of
the study. Exclusion criteria for control individuals were
the presence of chronic diseases associated with nonspe-
cific immunosuppression (diabetes, liver or renal diseases,
HIV infection, malnutrition, or malignant diseases) and
the use of immunosuppressive medication. BCG (bacillus
Calmette-Guerin) vaccination status was not consistently
available for all study participants. The etiology of end-
stage renal failure in hemodialysis patients was due to
glomerulonephritis (N = 28), pyelonephritis (N = 7), di-
abetic nephropathy (N = 39), polycystic kidney disease
(N = 11), vascular nephropathies (N = 10), systemic vas-
culitis (N = 2), interstitial diseases (N = 3), others (N =
12), and unknown (N = 15). Blood from patients was
drawn before the start of the hemodialysis session. The
study was approved by the local ethics committee, and all
individuals gave informed consent.
Stimulation of PPD-specific CD4 T cells within
whole blood
Stimulation of PPD-specific CD4 T cells was per-
formed from heparinized whole blood essentially as de-
scribed for the detection of virus-specific T cells [20,
22–24]. As a stimulus, titered amounts of PPD (222 IU/
mL, Tuberkulin GT-1000; Chiron Behring, Marburg, Ger-
many) or 10 lg/mL recombinant ESAT-6 protein (a kind
gift of A. Whelan, TB Research Group, Veterinary Lab-
oratories Agency, Weybridge, UK) were used in the pres-
ence of 1 lg/mL aCD28 and aCD49d (clones L293 and
9F10, BD, Heidelberg, Germany), respectively. As nega-
tive controls, cells were stimulated with the diluent that
was used to dissolve PPD (Chiron Behring). Cells were
incubated in polypropylene tubes at 37◦C at 6% CO2 for
a total of 6 hours. During the last 4 hours, 10 lg/mL of
Brefeldin A (Sigma, Deisenhofen, Germany) was added
to block extracellular secretion of cytokines. Thereafter,
the blood was treated with 2 mmol/L EDTA for 15 min-
utes. Subsequently, erythrocytes were lysed, and leuko-
cytes were fixed for 10 minutes using BD lysing solution
(BD). Cells were washed once with fluorescence-
activated cell sorter (FACS) buffer [phosphate-buffered
saline (PBS), 5% filtered fetal calf serum (FCS), 0.5%
bovine serum albumin (BSA), 0.07% NaN3] and pro-
cessed for flow cytometric analysis.
Determination of the frequency and characterization
of PPD- and ESAT-6–specific T cells
Fixed leukocytes were permeabilized with 2 mL FACS
buffer containing 0.1% saponin (Sigma) for 10 minutes
at room temperature. Thereafter, they were triple- or
quadruple-stained for 30 minutes at room temperature in
the dark using saturating conditions of the following anti-
bodies: anti-CD4 (clones SK3), anti-IFNc (clone 4S.B3),
anti-TNFa (clone Mab11), anti-CD69 (clone L78). In ad-
dition, the cell surface molecules CD45RO and CD27
were analyzed on cytokine-positive cells using antibody
clones UCHL1 and L128, respectively (all antibodies
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Fig. 1. Flow-cytometric quantitation of puri-
fied protein derivative (PPD)-specific CD4 T
cells. Representative dot plots of individuals
with (A) or without (B) detectable specific
T-cell reactivity toward PPD. Whole blood
was stimulated with control antigen (diluent)
or PPD and specifically induced interferon c
(IFNc) induction in CD4 T cells was analyzed
using flow cytometry. Numbers indicate the
percentage of specifically stimulated CD4 T
cells.
from BD). Thereafter, cells were washed once with 3 mL
of FACS buffer and fixed with 1% paraformaldehyde. At
least 15,000 CD4 T cells were analyzed on a FACS Cal-
ibur (BD) using Cellquest-Pro 4.0.2. The percentage of
specific T cells was calculated by subtraction of the fre-
quency obtained by the respective control stimulation.
The lower limit of detection was 0.05%.
Determination of PPD reactivity in vivo
Reactivity toward PPD in vivo was determined using
the skin test according to Mendel-Mantoux in accordance
with standard national German guidelines (Tuberkulin
GT-10; Chiron Behring). The test was carried out
according to the manufacturer’s instructions by the in-
tracutaneous inoculation of 10U of PPD into the volar
surface of the forearm. The resulting induration was de-
termined by three qualified persons (U.S., P.C., and U.M.)
48 to 72 hours thereafter and compared with the reactiv-
ity toward the diluent. An induration of 5 mm was chosen
as the internationally recognized cut-off for Mendel-
Mantoux skin-test reactivity. Exclusion criteria for the
performance of the skin test were a known history of tu-
berculosis infection, skin disorders, intercurrent pyrexiel
illness, or the lack of informed consent for the skin test.
Statistical analysis
Statistical analysis was performed using Prism V3.03
software (Graphpad, San Diego, CA, USA). Significant
differences were determined using the Mann-Whitney
test. Fisher exact test and v 2 test was used to analyze
differences between two or more groups of individuals
with respect to the prevalence of PPD reactivity or skin-
test responses. Correlations were calculated according to
Spearman.
RESULTS
Similar prevalence and frequency distribution of
PPD-specific CD4 T cells in immunocompetent
health care workers and hemodialysis patients
PPD-specific CD4 T cells were flow cytometrically
quantified from whole blood after stimulation with PPD
in vitro. The frequency of specific cells was determined as
the percentage of CD69 and interferon (IFN)c-positive
CD4 T cells. Characteristic examples of individuals reac-
tive and not reactive toward PPD are shown in Figure 1.
Whereas 0.46% of CD4 T cells were activated to produce
IFNc after stimulation with PPD (Fig. 1A), no such induc-
tion was observed in the individual shown in Figure 1B.
Within each individual, the diluent failed to induce
any relevant cytokine production. Nevertheless, the fre-
quency of PPD-specific CD4 T cells was calculated by
subtraction of the frequency obtained by the respective
control stimulation.
This flow cytometric assay was used to analyze the fre-
quencies of PPD-specific CD4 T cells in 127 hemodialysis
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Table 1. Hemodialysis patients and immunocompetent health care
workers do not differ in the prevalence of PPD reactivity in vitro
Blood Health care Hemodialysis
donors workers patients
N = 52 N = 107 N = 127
PPD-specific CD4 T 16 (30.8%) 52 (48.6%) 68 (53.5%)
cells >0.05%
PPD, purified protein derivative. Shown are the numbers and percentages
of individuals with PPD-specific CD4 T-cell reactivity above detection limit of
0.05%. There was a significant difference between blood donors and health care
workers or hemodialysis patients (P = 0.02).
patients and 159 immunocompetent individuals, respec-
tively. To account for the higher risk of hemodialysis
patients for regular exposure to infected patients, im-
munocompetent individuals were subdivided into a group
of blood donors with presumptive low-risk exposure, and
a cohort of health care workers at similarly increased
risk for exposure as hemodialysis patients. Among blood
donors, 30.7% of individuals (16/52) showed PPD-
specific CD4 T cells above the detection limit of 0.05%
(Table 1). In line with an increased risk for exposure,
this percentage was higher in both health care workers
and hemodialysis patients (P = 0.02, Table 1). Interest-
ingly, however, despite uremic immunodeficiency, there
was no difference in the prevalence of PPD-specific T-cell
reactivity between health care workers and hemodialy-
sis patients (48.6% and 53.5%, respectively; P = 0.51)
(Table 1). Although there was a considerable interindi-
vidual variation in the frequency of PPD-specific CD4
T cells among PPD-positive individuals that ranged from
0.06 to up to 4.12% (Fig. 2), median frequencies did not
differ between healthy individuals (0.17%, range 0.06 to
3.75%), and hemodialysis patients (0.26%, range 0.06 to
4.12%; P = 0.28; Fig. 2). Thus, PPD-specific T cells can be
quantified directly from whole blood, and the prevalence
of PPD reactivity is lower in blood donors compared
with the higher risk groups of hemodialysis patients and
health care workers. Interestingly, despite uremic immun-
odeficiency, neither the prevalence nor the frequency of
distribution differed between hemodialysis patients and
immunocompetent health care workers.
PPD-specific T cells predominantly consist of both
immature and mature memory cells of Th1 phenotype
Phenotypical analysis was carried out to character-
ize the differentiation status and the cytokine profile of
antigen-specific T cells. PPD-reactive T cells were shown
to produce IFNc upon specific stimulation (Fig. 1). This
cytokine induction was restricted to the CD4 T-cell subset
(data not shown). The phenotype and maturation status
of PPD-specific CD4 T cells was further characterized by
the analysis of various other cytokines and cell surface
markers (Fig. 3, Table 2). The induction of IFNc is in-
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Fig. 2. Heterogeneous frequencies of purified protein derivative
(PPD)-specific CD4 T cells in immunocompetent individuals (N = 52,
control patients) and hemodialysis patients (N = 68, HD patients) with
PPD-specific T-cell reactivity. Neither median T-cell frequencies nor
the frequency distribution differed between control individuals (me-
dian 0.17%, range from >0.05% to 3.75%) and hemodialysis patients
(median 0.26%, range from >0.05% to 4.12%; P = 0.28).
dicative of a Th1 phenotype. In line with this evidence, a
similar percentage of CD4 T cells was induced to produce
the Th1 cytokine TNFa (Fig. 3A), and there was a strong
correlation between the expression of both cytokines (r =
0.96, P < 0.0001; Fig. 3). In contrast, levels of Th2 cy-
tokines such as interleukin (IL)4 and IL5 were in general
below detection limit after stimulation with PPD (N = 13;
data not shown). The only exceptions were the hemodial-
ysis patients with the highest frequencies of PPD-reactive
IFNc and tumor necrosis factor (TNF)a–positive T cells
(4.12% and 4.24%, respectively), who concomitantly had
0.21% of IL4-positive cells.
The majority of PPD-specific T cells showed a memory
phenotype characterized by the expression of CD45RO
(e.g., 90.88% ± 8.11% of PPD-reactive CD4 T cells in
hemodialysis patients) (Table 2). The analysis of CD27
served as a marker to determine the differentiation sta-
tus of specific T cells. Interestingly, among PPD-specific
T cells, there were similar percentages of CD27 posi-
tive and negative cells, indicating the existence of both
recently activated and terminally differentiated T cells,
respectively (CD27 positive: 54.20 + 18.97% in hemodial-
ysis patients) (Table 2). There were no differences in the
phenotype of PPD-specific T cells between hemodialy-
sis patients and control patients (Table 2). A representa-
tive example, where all PPD-specific T cells were positive
for CD45RO and 51.52% of the respective T cells were
positive for CD27 is shown in Fig. 3A. Taken together,
PPD-specific CD4 T cells predominantly comprise both
recently activated as well as terminally differentiated
memory cells of a Th1 phenotype.
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Fig. 3. Phenotypic characterization of purified protein derivative (PPD)-specific CD4 T cells. Dot plots of the flow-cytometric analysis of CD45RO
and CD27 expression among cytokine-positive CD4 T cells after stimulation with PPD (A). Numbers denote the frequencies of activated (CD69-
positive) interferon c (INFc) or tumor necrosis factora (TNFa)-positive T cells among all CD4 T cells (upper panel), or the percentage of CD27-
or CD45RO-positive T cells among cytokine-positive cells (lower panel). A significant correlation exists between the percentage of PPD-specific
CD4 T cells producing IFNc or TNFa, respectively (r = 0.96, P < 0.0001; N = 134) (B).
Table 2. PPD-specific CD4 T cells comprise both recently activated
as well as mature memory Th1 cells
Hemodialysis
patients Percentage among cytokine-positive T cells N
Phenotype
CD27 positive 54.20 ± 18.97% 43
CD45RO positive 90.88 ± 8.11% 51
Controls
Phenotype Percentage among cytokine-positive T cells N
CD27 positive 59.90 ± 14.90% 32
CD45RO positive 87.73 ± 11.37% 28
PPD, purified protein derivative. Numbers indicate the percentage of cells
positive for the expression of CD45RO and CD27 among cytokine-positive CD4
T cells stimulated with PPD. There was no difference in the phenotype of PPD-
specific CD4 T cells between immunocompetent individuals and hemodialysis
patients.
Lower percentage of skin test–positive individuals
among hemodialysis patients
In order to compare the in vitro reactivity toward PPD
with the reactivity in vivo, a standard skin test according
to Mendel-Mantoux was carried out in both immuno-
competent individuals and hemodialysis patients. Im-
munocompetent individuals comprised both health care
workers (N = 23) and immunocompetent nonuremic pa-
tients (N = 33) (Table 3). As expected, among individ-
uals with PPD-specific T-cell frequencies below 0.05%,
the majority (20/21 control patients and 29/29 hemodial-
ysis patients) had an induration below 5 mm. Conversely,
a positive skin test was found in 91.7% of health care
workers and 82.6% of control patients with PPD reac-
tivity above 0.05% (Table 3). In large contrast, how-
Table 3. Lower sensitivity of the skin test in hemodialysis patients
compared with immunocompetent control patients
Health care Control Hemodialysis
workers patients patients
PPD-specific T cells >0.05% N = 12 N = 23 N = 35
Skin-test >5 mm 11 (91.7%) 19 (82.6%) 18 (51.4%)
PPD, purified protein derivative. Shown is the percentage of individuals with
an induration >5mm among individuals with PPD-specific T-cell frequencies
above 0.05%. Median skin-test induration was 15 mm (range 0 to 35 mm) for
control patients (health care workers and control patients), and 8 mm (range 0 to
78 mm) for hemodialysis patients. Twenty out of 21 immunocompetent control
patients and 29/29 hemodialysis patients with PPD reactivity below 0.05% had
an induration smaller than 5 mm. There was no difference in sensitivity between
health care workers and immunocompetent control patients.P = 0.007.
ever, a significantly lower percentage of positive skin
tests was found among PPD-positive hemodialysis pa-
tients (51.4%, P = 0.007) (Table 3).
Interestingly, a significant correlation was observed be-
tween the frequency of PPD-reactive CD4 T cells and the
respective induration in the skin test, although the cor-
relation was less tight in hemodialysis patients (immuno-
competent controls: r = 0.72, P < 0.0001; hemodialysis
patients: r = 0.64, P < 0.0001) (Fig. 4). Together, this
suggests that the flow cytometric quantitation of PPD-
specific CD4 T cells may represent a sensitive assay to
detect PPD reactivity ex vivo. Moreover, in the face of
similar prevalences of PPD reactivity (Fig. 2) and a de-
creased sensitivity of the skin test in hemodialysis pa-
tients compared with immunocompetent control patients
(Table 3 and [5, 6]), the flow cytometric assay may be of
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Fig. 4. Correlation between induration and
purified protein derivative (PPD)-specific T-
cell frequencies. A significant correlation ex-
ists between the frequency of PPD-specific
CD4 T cells and the induration in skin test
in control individuals (A) (health care work-
ers and immunocompetent control patients,
r = 0.72, P < 0.0001, N = 56) and hemodial-
ysis patients (r = 0.64, P < 0.0001, N = 63)
(B).
particular value for the sensitive detection of PPD reac-
tivity in immunocompromised individuals.
Reactivity toward ESAT-6 allows the identification of
a latent infection among PPD-positive individuals
PPD is a complex mixture of proteins that may also
detect T-cell reactivity toward vaccinations using the M.
bovis BCG strain. Thus, PPD-specific T-cell reactivity in
the skin test or in the flow cytometric assay may either be
the result of an actual latent tuberculosis infection, and/or
may reflect the response toward a previous BCG vacci-
nation. To distinguish between these possibilities, T cells
were stimulated using the recombinant ESAT-6 protein
that is absent from all strains of the M. bovis BCG vaccine.
After stimulation of whole blood with PPD and ESAT-
6 antigen, differential response patterns were observed.
Dotplots of the flow cytometric analysis of T cells reactive
toward ESAT-6 in PPD-positive and -negative individu-
als are shown in Figure 5A to C. Interestingly, whereas
the individual shown in Figure 5A exhibited T-cell reac-
tivity toward both PPD (0.77%) and ESAT-6 (0.40%),
the T-cell response of the individual shown in Figure 5B
was restricted to PPD only. Moreover, individuals lack-
ing a response toward PPD never showed any reactivity
toward ESAT-6 (Fig. 4C, and data not shown). Among
a total of 36 PPD-positive HD patients who were ana-
lyzed, 18 had detectable T-cell responses toward ESAT-6
(Fig. 4D). Similarly, among a group of 37 immunocom-
petent control individuals with detectable PPD-specific
T-cell reactivity, 15 were also positive for ESAT-6 (data
not shown). Interestingly, there was a significant corre-
lation between the frequencies of specific CD4 T cells
that were stimulated by PPD and ESAT-6 (r = 0.72, P <
0.0001), and the differentiation status of ESAT-6 reactive
cells did not differ from PPD-specific T cells (55.07 ±
24.01% CD27-positive cells among ESAT-6 reactive
T cells) (compare with Table 2). Taken together, although
BCG vaccination status was not consistently available,
the presence of T cells reactive toward ESAT-6 is strongly
indicative of a latent M. tuberculosis infection, and is not
a result of previous BCG vaccination [19, 25, 26].
DISCUSSION
In this study, the prevalence of latent M. tubercu-
losis infection was characterized in healthy individuals
and hemodialysis patients with uremic immunodefi-
ciency, and the frequencies and phenotypic characteris-
tics of PPD-specific CD4 T cells were analyzed using a
rapid flow cytometric whole-blood assay. Interestingly,
the prevalence of PPD reactivity was lower in immuno-
competent individuals with low risk of exposure com-
pared with the higher risk groups of both health care
workers and hemodialysis patients. The latter groups,
however, did not differ with respect to prevalences or
frequency distributions of PPD-specific T cells. Given the
well-known impaired responsiveness of hemodialysis pa-
tients in skin tests [5, 6], our findings indicate that the
whole blood assay may have potential as a useful alter-
native to skin testing, and suggest that this assay may have
an improved sensitivity for the diagnosis of a latent tu-
berculosis infection in immunocompromised individuals.
Interestingly, a significant correlation was found be-
tween the frequencies of PPD-reactive T cells and the size
of the skin-test induration. This is conceivable, as both the
skin test and the whole-blood assay rely on similar im-
munologic principles [27]. Both assay systems are based
on the specific induction of inflammatory cytokines by
T cells that have previously been sensitized to mycobac-
terial antigens in vivo. In the skin test, the characteristic
induration is caused by the infiltration of PPD-specific
lymphocytes, resulting in a local inflammatory response
at the site of injection [16]. In the whole-blood assay, the
induction of cytokines is used as a measure to directly
quantitate PPD-reactive T cells after specific stimulation
in vitro. Our data show that the sensitivity of the skin test
is similar to the T cell–based test in immunocompetent
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Fig. 5. Identification of latently infected individuals using the early secretory antigenic target-6 (ESAT-6) antigen. Representative dot plots of
individuals with or without a specific T-cell reactivity toward purified protein derivative (PPD) or ESAT-6 (A-C). Whole blood was stimulated with
control antigen (diluent, not shown), PPD, or ESAT-6, and specifically induced interferon c (IFNc) induction in CD4 T cells was analyzed using flow
cytometry. Numbers indicate the percentage of specifically stimulated CD4 T cells. Specific T-cell frequencies toward ESAT-6 were analyzed in 36
PPD-positive hemodialysis patients, and 18 individuals had ESAT-6–specific T cells above 0.05% (D). T-cell frequencies toward PPD and ESAT-6
showed a significant correlation (r = 0.70, P < 0.0001).
individuals (Table 3). In immunocompromised individu-
als, however, a far lower sensitivity was observed for the
skin test, as has been previously described [5, 6]. This may
be a consequence of the impaired costimulatory capacity
of uremic antigen–presenting cells and cellular immune
reactivity in vivo [7, 8, 10, 11]. In contrast, hemodialysis
patients did not show impaired PPD reactivity in vitro,
suggesting that the sensitivity of this T cell–based test
may be unaffected by immunosuppression. This may in
part be because the in vitro assay allows optimization of
stimulatory conditions to reveal a maximum amount of
the individual T-cell reactivity. This is mainly achieved
by the addition of costimulatory antibodies, which were
shown to lead up to a 3-fold increase in the detection
of actual T-cell frequencies without causing nonspecific
activation [28].
The sensitive identification of latent infections may
help to target preventative antibacterial prophylaxis to
immunocompromised patients. This may be particularly
relevant for latently infected hemodialysis patients await-
ing or undergoing transplantation, as the risk of active
disease is increased 10-fold in hemodialysis patients and
50-fold in transplant recipients [29]. In the setting of trans-
plantation, preventative prophylaxis is recommended
for patients with a previous history of tuberculosis, or
for patients with strong skin-test reactivity [17, 18]. In
immunocompetent individuals, M. tuberculosis–specific
immune responses are generally sufficient to maintain
long-term immune control and clinical latency. Immuno-
suppressive treatment, however, may result in the dis-
ruption of this well-balanced equilibrium, and in the
progression to symptomatic active tuberculosis. In line
with this evidence, active tuberculosis is often associated
with falsely negative skin tests [16] and reduced levels of
PPD-specific immunity in circulation [30, 31]. This situa-
tion is reminiscent of the specific T-cell immunity against
a number of persistent viruses such as cytomegalovirus
(CMV), where an equilibrium between specific immu-
nity and viral replication exists. We have recently shown
in the setting of renal transplantation, that stable levels
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of CMV-specific T cells correlate with an efficient control
of viral replication, whereas a decrease of CMV-specific
CD4 T cells is associated with the progression to symp-
tomatic CMV disease [22]. Thus, it is tempting to spec-
ulate whether the serial analysis of PPD-specific T-cell
immunity in latently infected patients may similarly be
applied for the monitoring of infectious complications
after transplantation.
In the past years, particular interest was focused on
deleted regions in the genome of the M. bovis BCG
strain. T-cell responses to ESAT-6 and CFP-10, anti-
gens encoded by genes that are deleted from BCG but
present in M. tuberculosis, can discriminate latently in-
fected patients from individuals vaccinated with BCG or
sensitized to nontuberculous mycobacteria [25–27, 32–
34]. Based on stimulation with PPD alone, neither the
skin test nor the in vitro flow cytometric assay allows a
clear-cut distinction. Clinical observations indicate that
cross-reactions derived from BCG vaccinations tend to
result in smaller amounts of induration than reactions
caused by M. tuberculosis, although overlap exists [18,
35]. Conversely, latent infections are rather associated
with stronger delayed-type hypersensitivity responses. In
line with this evidence, T-cell reactivity toward ESAT-6
was primarily found in individuals with high frequencies
of PPD-specific T cells (Fig. 4D). This indicates that high
levels of PPD reactivity are associated with positive re-
sponses toward ESAT-6, and are particularly suggestive
of latent M. tuberculosis infection. Conversely, low lev-
els of PPD reactivity may correlate with vaccination re-
sponses. Our data may suggest a rough estimate of the
thresholds of PPD reactivity that may be indicative of
an actual latent infection. In the current study, a PPD-
reactivity above approximately 0.3% was associated with
a positive T-cell response toward ESAT-6 in 74% of all
cases (Fig. 4D). Together these data highlight how a la-
tent infection imposes a constant challenge on the host
immune system to maintain high levels of protective cel-
lular immunity.
Similar to M. tuberculosis, viruses such as HIV-1,
Epstein-Barr virus, CMV, or hepatitis C virus are char-
acterized by the establishment of lifelong infection in the
human host, where their replication is tightly controlled
by virus-specific cellular immune responses [36–40]. In-
terestingly, the differentiation phenotype of antigen-
specific T cells may differ considerably depending on the
viral specificity, and on the infection status of the host
[41–43]. During primary infections, specific T cells are
generally characterized by the expression of CD27, which
is indicative of a recently activated phenotype [41, 44].
Interestingly, PPD-specific T cells are memory cells con-
taining equal amounts of both CD27-positive as well as
terminally differentiated T cells (CD27-negative; Fig. 4A
and Table 3). Along with the presence of stable T-cell fre-
quencies over time, this mixed phenotype may indicate
the need for a constant supply of PPD-reactive T cells as
a consequence of regular bacterial challenge.
CONCLUSION
Taken together, the use of a rapid flow cytometric assay
was evaluated for the sensitive detection of latent infec-
tion with M. tuberculosis in immunocompromised indi-
viduals. So far, this has not been shown for other tests
that analyze T-cell function, such as proliferation assays
or enzyme-linked immunosorbent assay (ELISA)-based
QuantiFERON approaches [45, 46]. One other T-cell test,
the enzyme-linked immunospot (ELISPOT) assay, how-
ever, also allows for an accurate quantitation of specific
T cells at the single-cell level. This approach was sim-
ilarly effective in detecting T-cell responses toward M.
tuberculosis in immunocompromised individuals; unlike
the skin test, it was not adversely affected by HIV in-
fection [32]. The low threshold for detection of antigen-
specific T cells in ELISPOT (0.004% of peripheral blood
mononuclear cells) may explain its high diagnostic sen-
sitivity and its widespread utility in a number of clinical
settings [19, 25, 26, 32]. However, the flow cytometric ap-
proach has certain advantages, as it may be performed
directly from whole blood from small sample volumes
(<1 mL) without the need of cell isolation before stimu-
lation. Apart from quantitation of antigen-specific T cells,
it also enables simultaneous immunophenotyping of re-
active T cells with respect to T-cell subpopulations, dif-
ferentiation status, and cytokine profiles. Additionally, in
vitro assays in general have a number of advantages over
the use of the established skin test. First, they can be per-
formed directly from whole blood within a single day and
do not require several visits by the patient for placing and
reading of the test. Second, no particular exclusion crite-
ria exist, because the tests can be applied in patients with
skin disorders or in patients with a previous history of
tuberculosis infection. Third, there is no need to do serial
tests with increasing doses of antigen, and tests can be re-
peated on separate occasions without being confounded
by the booster effect on specific immunity in vivo. Finally,
the potential to conveniently characterize and quanti-
tate immune responses toward selected mycobacterial
antigens or antigenic mixtures enables us to distinguish
actual latent infection from purely vaccination-induced
responses.
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